"Weight Loss Drugs Mounjaro and Zepbound Show Promise in Lowering Blood Pressure"

The newest obesity drug, tirzepatide, developed by Eli Lilly, has shown potential to help manage blood pressure in addition to aiding weight loss. Clinical trial participants experienced a drop in systolic blood pressure over a six-month period compared to a placebo group. This dual-action drug, mimicking important hormones for hunger and metabolism, has demonstrated significant weight loss potential, with some participants losing over 20% of their baseline weight. The findings suggest that tirzepatide and similar drugs may offer broader health benefits beyond weight loss, particularly for individuals at higher risk of heart-related issues.